

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/570,734
Filing Date	October 18, 2006
First Named Inventor	Fernando Albericio Palomera
Art Unit	1654
Examiner Name	Ronald T. Niebauer
Attorney Docket Number	13566.105010

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US 6,274,551	08-14-2001	Scheuer	
		US 2002/0164386	11-07-2002	Meisner	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴ - Number ⁵ - Kind Code ⁶ (if known)				

Examiner
Signature

Date
Considered

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of the form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Article One of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Error Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. If it is possible, Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete the form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/570,734
Filing Date	October 18, 2006
First Named Inventor	Fernando Albericio Palomera
Art Unit	1654
Examiner Name	Ronald T. Niebauer
Attorney Docket Number	13566.105010

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Angel Lopez i Macia, Ph.D. Thesis, Departament de Química Organica. Facultat de Química Divisio de Ciències Experimentals i Matemàtiques, Universitat de Barcelona, catalogued January 18, 2001	
		English translation: Angel Lopez i Macia, Ph.D., Thesis, Departament de Química Organica. Facultat de Química Divisio de Ciències Experimentals i Matemàtiques, Universitat de Barcelona, catalogued January 18, 2001, chapters 3.4 and Conclusion	
		Bertino et al., Principles of Cancer Therapy, Cecil Textbook of Medicine, vol. 1, pp. 1061-1074, 2000	
		Jose Carlos Jimenez Garcia, Ph.D. Thesis, University of Barcelona, March 29, 2004	
		Greaves et al., "Treatment of Psoriasis," The New England Journal of Medicine, 332(9), pages 581-588	
		Schellens et al., "Phase I and Pharmacokinetic Study of Kahalalide F in Patients with Advanced Androgen Resistant Prostate Cancer," American Society of Clinical Oncology, May 18-21, 2002, vol. 21, part 1 of 2, p.113a	
		Schellens et al., "Phase I and Pharmacokinetic Study of Kahalalide F in Patients with Advanced Androgen Refractory Prostate Cancer," AACR-NCI-EORTC International Conference, 2001	
		Suggitt et al., "50 Years of Preclinical Anticancer Drug Screening: Empirical to Target-Driven Approaches," Clinical Cancer Research, vol. 11, February 1, 2005, pp. 971-981	

Examiner Signature	/Ronald Niebauer/	Date Considered	09/17/2009
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 422 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.